- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02405221
Safety and Feasibility of TA-CIN Vaccine in HPV16 Associated Cervical Cancer
A Pilot Clinical Trial Assessing the Safety and Feasibility of Intramuscular Administration of the TA-CIN Vaccine as Adjuvant Therapy for Patients With History of HPV16 Associated Cervical Cancer
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a randomized, multi-center, open label pilot study. The primary goal of this study is to determine the safety of TA-CIN vaccine as adjuvant therapy, and to assess evidence of induction of HPV antigen-specific immunologic response when administered at different locations (arm or thigh). In this pilot study, a single dose level (100µg) assessment of the safety and tolerability of administering TA-CIN vaccine three times to either the arm versus the thigh of patients who have previously been treated for HPV16-related cervical cancer in the past year and are documented to have no evidence of disease recurrence based on standard-of-care imaging and/or clinical assessment upon eligibility.
A total of 14 patients will be enrolled to assess the safety of TA-CIN vaccine via different injection sites as adjuvant therapy. Safety assessments will continue for a period for 1 month after the last vaccination. Few or no serious adverse events (SAEs) are expected from this regimen and routes of administration. The motivation for the design is to confirm that the dose and site of injection implemented here has minimal or no systemic toxicity, as well as determining the preferred injection site that can elicit more potent immune response.
The study will consist of the following parts:
- Screening evaluation
- Dosing period and response assessments
- Follow-up visits after last dose
Screening Evaluation:
The screening visit will be performed within 60 days of the first study drug administration visit. The study team will check the results of these screening tests to see if patient qualifies to participate.
Dosing Period:
Those who meet the study requirements during the screening period will then begin the dosing phase of this study. TA-CIN will be given as a single intramuscular injection every 4 weeks for a maximum of 3 times. The location of the injection (arm or thigh) will depend on randomization. Patients will be assessed for safety and response to treatment during this period.
Follow-Up Period:
Four follow-up evaluations will be performed during a clinic visit after the last dose of the vaccine. These will take place at the following time points: (1) 1-3 weeks after the last dose of the study drug, (2) about 6 months after the last dose of the study drug, (3) about 12 months after the last dose of the study drug, and (4) about 24 months after the last dose of the study drug.
Study Type
Enrollment (Estimated)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Alabama
-
Birmingham, Alabama, United States, 35233
- Women & Infants Center, University of Alabama at Birmingham
-
-
Maryland
-
Baltimore, Maryland, United States, 21287
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients with HPV16 related stage IB1-IV cervical cancer who completed definitive treatment within 12 months
- Patients with no evidence of disease recurrence within 8 weeks of enrollment
- Documented to have HPV16 nucleic acid within the cervical tumor specimen as determined by in situ hybridization
- Fresh-frozen or paraffin-embedded material must be available for in situ hybridization testing for HPV16 nucleic acid for central confirmation
- Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 1
- Adequate organ function as defined by study-specified laboratory tests
- Ability to understand and willingness to sign a written informed consent document
- Willing and able to comply with study schedule and other protocol requirements
Exclusion Criteria:
- Currently have or have history of certain study-specified heart, liver, kidney, lung, neurological, immune or other medical conditions
- Patients with a diagnosis of immunosuppression or prolonged, active use of immunosuppressive agents such as systemic steroids
- Prior HPV vaccination
- Had surgery, chemotherapy, or radiation therapy within 28 days prior to receiving study drug
- Another investigational product within 28 days prior to receiving study drug
- Active or chronic HIV, HBV, or HCV infection
- Pregnant or lactating
- Patients who have an active autoimmune disease
- Patients with a recognized immunodeficiency disease or are being chronically treated with immunosuppressive drugs
- Women of childbearing potential
- Patients with non-healed wounds
- A history of current or recent concurrent malignancy (≤5 years) except basal cell cancer.
- Inability to understand or unwillingness to sign an informed consent document
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: TA-CIN administration via thigh
Each dose of TA-CIN vaccine is fixed, 100µg.
Patients will receive 3 doses of the TA-CIN 4 weeks apart (Weeks 1, 5, and 9), administered in the thigh.
Patients will be followed for 2 years after the 1st dose is given.
|
TA-CIN vaccine 100µg IM in the arm at Week 1, 5, and 9.
Other Names:
|
Experimental: TA-CIN administration via arm
Each dose of TA-CIN vaccine is fixed, 100µg.
Patients will receive 3 doses of the TA-CIN 4 weeks apart (Weeks 1, 5, and 9), administered in the arm.
Patients will be followed for 2 years after the 1st dose is given.
|
TA-CIN vaccine 100µg IM in the arm at Week 1, 5, and 9.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety and feasibility as assessed by Number of Participants with treatment-related Adverse Events
Time Frame: 4 years
|
Safety and feasibility of intramuscular TA-CIN vaccine via arm or thigh as assessed by number of participants with with a history of HPV16 associated IB1-IV cervical cancer experiencing treatment-emergent adverse events as defined by CTCAE v4.0.
|
4 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Antibody Response as measured by level of circulating antibody in peripheral blood
Time Frame: up to 4 years
|
Level of circulating antibody to HPV16 E6, E7, and L2 in the peripheral blood pre- and post-vaccination (visualized by ELISA).
|
up to 4 years
|
T-Cell Response as measured by level of circulating T-cells in peripheral blood
Time Frame: up to 4 years
|
Level of circulating HPV16 E6- and E7- specific CD8+ T cells and/or CD4+ T cells in the peripheral blood pre- and post-vaccination (visualized by ELISPOT)
|
up to 4 years
|
Mononucleocyte Response
Time Frame: up to 4 years
|
Proliferative responses of peripheral blood mononucleocytes pre- and post-vaccination in response to stimulation by HPV16 E6, E7 and L2
|
up to 4 years
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Circulating HPV16 E6-/E7-specific CD8+ T cells
Time Frame: up to 4 years
|
Levels of circulating HPV16 E6- and E7-specific CD8+ T cells in the peripheral blood pre- and post-vaccination (measured using T-cell receptor sequencing)
|
up to 4 years
|
Levels of HPV-specific neutralizing antibodies
Time Frame: up to 4 years
|
Levels of HPV-specific neutralizing antibodies in the peripheral blood pre- and post-vaccination
|
up to 4 years
|
Residual HPV16 Viral Load
Time Frame: 4 years
|
Residual HPV16 viral load in plasma
|
4 years
|
Clinical Response as measured by Time to Disease Recurrence
Time Frame: 4 years
|
Clinical response associated with vaccine induced immune responses as measured by Time from administration of TA-CIN to disease recurrence.
|
4 years
|
Collaborators and Investigators
Investigators
- Principal Investigator: Stephanie Gaillard, MD, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Uterine Neoplasms
- Genital Neoplasms, Female
- Uterine Cervical Diseases
- Uterine Diseases
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Urogenital Diseases
- Genital Diseases
- Genital Diseases, Female
- Uterine Cervical Neoplasms
Other Study ID Numbers
- J1553
- P50CA098252 (U.S. NIH Grant/Contract)
- IRB00054202 (Other Identifier: JHMIRB)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HPV16 Associated Cervical Cancer
-
Sidney Kimmel Comprehensive Cancer Center at Johns...National Cancer Institute (NCI); National Institutes of Health (NIH)CompletedHPV16 Positive | Cervical Intraepithelial Neoplasia (CIN 2/3)United States
-
TScan Therapeutics, Inc.RecruitingMelanoma | Cervical Cancer | Head and Neck Cancer | Ovarian Cancer | Non Small Cell Lung Cancer | HPV16 Related CancersUnited States
-
Memorial Sloan Kettering Cancer CenterHookipa Biotech GmbH; NaverisRecruitingHPV16+ Squamous Cell CarcinomaUnited States
-
University of California, San DiegoWithdrawnCervical Cancer | Cervical Cancer Stage | Cervical Cancer Stage IB2 | Cervical Cancer Stage IB1 | Cervical Cancer Stage I | Cervical Cancer Stage IB | Cervical Cancer Stage II | Cervical Cancer Stage IIa | Cervical Cancer, Stage IIB | Cervical Cancer, Stage III | Cervical Cancer Stage IIIB | Cervical Cancer... and other conditionsUnited States
-
M.D. Anderson Cancer CenterWithdrawnStage IB3 Cervical Cancer FIGO 2018 | Stage II Cervical Cancer FIGO 2018 | Stage IIA Cervical Cancer FIGO 2018 | Stage IIA1 Cervical Cancer FIGO 2018 | Stage IIA2 Cervical Cancer FIGO 2018 | Stage IIB Cervical Cancer FIGO 2018 | Stage III Cervical Cancer FIGO 2018 | Stage IIIA Cervical Cancer FIGO... and other conditions
-
Abramson Cancer Center of the University of PennsylvaniaWithdrawnCervical Cancer | Stage IB Cervical Cancer | Stage IIA Cervical Cancer | Stage IIB Cervical Cancer | Stage III Cervical Cancer | Stage IVA Cervical Cancer
-
National Cancer Institute (NCI)CompletedCervical Adenocarcinoma | Cervical Squamous Cell Carcinoma | Stage IB Cervical Cancer | Stage IIA Cervical Cancer | Stage IIB Cervical Cancer | Stage III Cervical Cancer | Stage IVA Cervical Cancer | Stage IVB Cervical CancerUnited States
-
Masonic Cancer Center, University of MinnesotaRecruitingCancer | HPV Associated CancerUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingStage IA Cervical Cancer | Stage IB Cervical Cancer | Stage IA1 Cervical Cancer | Stage IA2 Cervical Cancer | Stage IB1 Cervical Cancer | Stage IB2 Cervical Cancer | Stage IB3 Cervical CancerUnited States
-
Mayo ClinicNational Cancer Institute (NCI)RecruitingCervical Adenosquamous Carcinoma | Cervical Squamous Cell Carcinoma, Not Otherwise Specified | Recurrent Cervical Carcinoma | Stage IB3 Cervical Cancer FIGO 2018 | Stage II Cervical Cancer FIGO 2018 | Stage IIA Cervical Cancer FIGO 2018 | Stage IIA1 Cervical Cancer FIGO 2018 | Stage IIA2 Cervical... and other conditionsUnited States
Clinical Trials on TA-CIN (thigh)
-
University of Alabama at BirminghamJohns Hopkins UniversityRecruiting
-
Sidney Kimmel Comprehensive Cancer Center at Johns...WithdrawnRecurrent Human Papillomavirus Type 16 Associated CancerUnited States
-
Assiut UniversityUnknown
-
CinDome Pharma, Inc.CompletedGastroparesisUnited States
-
AstraZenecaActive, not recruitingPrimary Aldosteronism | HyperaldosteronismUnited States
-
Federal University of São PauloUnknownObesity | LymphedemaBrazil
-
CinDome Pharma, Inc.Terminated
-
Pennington Biomedical Research CenterNerium Biotechnology IncWithdrawn
-
AstraZenecaCompletedHypertensionUnited States
-
University of PennsylvaniaCompleted